natgillin/translations-raw huggingface dataset:
Hos patienter, der samtidig får nicorandil og NSAID'er, herunder ASA og LAS, er der en øget risiko for alvorlige komplikationer i form af gastrointestinal blødning, perforation og blødning (se pkt.
In patients concomitantly receiving nicorandil and NSAIDs including ASA and LAS, there is an increased risk for severe complications such as gastrointestinal ulceration, perforation and haemorrhage (see section 4.4).
Bivirkninger med ikke kendt hyppighed (kan ikke vurderes ud fra forhåndenværende data): Perforeret mavesår, ringen for ørerne, nedsat hørelse, pludselige, livstruende allergiske reaktioner eller overfølsomhedsreaktioner med bryst- eller mavesmerter, nyresygdom, lavt blodsukker, urinsur gigt (en tilstand med smertefulde, hævede led forårsaget af urinsyrekrystaller), forværring af madallergi og en særlig form for anæmi (lavt antal røde blodceller) (se afsnit 2 'Advarsler og forsigtighedsregler'), hævelse.
Side effects with frequency not known (frequency cannot be estimated from the available data): Ulcer perforation, ringing in the ears, hearing loss, sudden life-threatening allergic or hypersensitivity reactions with chest or abdominal pain, kidney disease, low blood sugar, gout (a condition of painful, swollen joints caused by uric acid crystals) and worsening of food allergies, a particular form of anaemia (low number of red blood cells) (see section 2 ‘Warnings and precautions'), swelling.
Clopidogrel/Acetylsalicylic acid Mylan bør anvendes med forsigtighed hos patienter med peptisk ulcus, gastroduodenal blødning eller mindre øvre gastrointestinale symptomer i anamnesen, da disse kan være tegn på gastrisk ulceration, der kan føre til gastrisk blødning.
Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients with a history of peptic ulcer or gastroduodenal haemorrhage or minor upper GI symptoms as this may be due to gastric ulceration which may lead to gastric bleeding.
Som dobbelt antitrombotisk middel skal Clopidogrel/Acetylsalicylic acid Mylan anvendes med forsigtighed til patienter med øget risiko for blødning pga. traumer, kirurgi eller andre patologiske tilstande samt til patienter, der samtidigt behandles med andre NSAID'er inklusive Cox-2 hæmmere, heparin, glykoprotein IIb/IIIa-hæmmere, selektive serotoningenoptagelseshæmmere (SSRI'er), trombolytika eller andre lægemidler forbundet med risiko for blødning, såsom pentoxifyllin (se pkt.
As a dual antiplatelet agent, Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), thrombolytics, or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Hvis Clopidogrel/Acetylsalicylic acid Mylan seponeres, kan patienterne have gavn af fortsat behandling med et trombocytfunktionshæmmende lægemiddel.
If the use of Clopidogrel/Acetylsalicylic acid Mylan is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
Clopidogrel/Acetylsalicylic acid Mylan forlænger blødningstiden og bør anvendes med forsigtighed hos patienter med læsioner, der indebærer øget blødningstendens (specielt gastrointestinalt og intraokulært).
Clopidogrel/Acetylsalicylic acid Mylan prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Clopidogrel/Acetylsalicylic acid Mylan indeholder clopidogrel og acetylsalicylsyre (ASA) og tilhører en gruppe medicin, der kaldes blodfortyndende medicin.
Clopidogrel/Acetylsalicylic acid Mylan contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products.
• På grund af risiko for hæmolyse skal dette lægemiddel administreres under omhyggelig medicinsk supervision til patienter med glucose-6-fosfatdehydrogenase (G6PD)-mangel (se pkt.
• This medicinal product must be administered under close medical supervision in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolysis (see section 4.8).
Tørremidlet må ikke sluges.
The desiccant should not be eaten.
Indeholder lactose og Allura Red AC.
Contains lactose and Allura Red AC. See leaflet for further information.
• Akut koronarsyndrom uden elevation af ST-segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker) inklusive patienter, som får indsat stent efter perkutan koronar intervention
• Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention
Glycerol monocaprylocaprat (E422)
Glycerol monocaprylocaprate (E422) Sodium lauril sulfate
Patienterne blev randomiseret til at modtage enten prasugrel 5 eller 10 mg/d (dag 0-14) (n = 1306) eller prasugrel 5 eller 10 mg/d (dag 0-7), derefter de-eskaleret til clopidogrel 75 mg/d (dag 8-14) (n = 1309) i kombination med ASA (< 100 mg/dag).
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1306), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1306), in combination with ASA (<100 mg/day).
Clopidogrel/Acetylsalicylic acid Mylan påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Clopidogrel/Acetylsalicylic acid Mylan has no or negligible influence on the ability to drive and use machines.
Clopidogrel er et prodrug, hvor en af metabolitterne hæmmer trombocytaggregationen.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
• udsætte fostret for: - Kardiopulmonal toksicitet (med præmatur lukning af ductus arteriosus og pulmonal hypertension); - Renal dysfunktion, der kan udvikle sig til nyresvigt med oligo-hydroamniose;
From the beginning of the sixth month of pregnancy, all prostaglandin synthesis inhibitors may expose: the foetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
HDPE tabletbeholdere med hvide, gennemsigtige skruelåg af polypropylen med påsat aluminiumsforseglingsindlæg i kartonæsker, der indeholder 100 filmovertrukne tabletter.
HDPE bottles with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant containing 100 film-coated tablets.
Acetylsalicylsyre hæmmer trombocytaggregation ved irreversibel hæmning af prostaglandincyklooxygenase og hæmmer derved dannelsen af tromboxan A2, en inducer af trombocytaggregation og vasokonstriktion.
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclooxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Patienterne fik clopidogrel (75 mg/dag, n = 22.961) plus ASA (162 mg/dag) eller ASA alene (162 mg/dag) (n = 22.891) i 28 dage eller indtil udskrivelse fra hospitalet.
Patients received clopidogrel (75 mg/day, n=22,961) plus ASA (162 mg/day), or ASA alone (162 mg/day) (n=22,891), for 28 days or until hospital discharge.
Øjenblødning (konjunktival, okulær, retinal)
Eye bleeding (conjunctival, ocular, retinal)
Patienter skal vejledes vedrørende risikoen for skader og blødning i mave-tarm-kanalen, hvis de drikker alkohol under behandlingen med clopidogrel plus ASA, især hvis alkoholforbruget er kronisk eller stort.
Patients should be counselled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy.
Ved midlertidig seponering af trombocythæmmende behandling bør Clopidogrel/Acetylsalicylic acid Mylan seponeres 7 dage før kirurgisk indgreb.
If patients must temporarily stop antiplatelet therapy, Clopidogrel/Acetylsalicylic acid Mylan should be discontinued 7 days prior to surgery.
Clopidogrel/Acetylsalicylic acid Mylan er et fast-dosis- kombinationspræparat til fortsat behandling ved:
Clopidogrel/Acetylsalicylic acid Mylan is a fixed-dose combination medicinal product for continuation of therapy in:
Brug af anden medicin sammen med Clopidogrel/Acetylsalicylic acid Mylan Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nyligt.
Other medicines and Clopidogrel/Acetylsalicylic acid Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Blødning i luftvejene (hæmoptyse, pulmonal blødning), bronkospasmer, interstitiel pneumoni, ikkekardiogent lungeødem ved kronisk brug eller i forbindelse med en overfølsomhedsreaktion på grund af acetylsalicylsyre eosinofil pneumoni.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, noncardiogenic pulmonary oedema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
• hvis du har aktiv blødning såsom et mavesår eller blødning i hjernen.
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
Hjælpestoffer, som behandleren skal være opmærksom på Hver filmovertrukket tablet indeholder 48 mg lactose
Excipients with known effect Each film-coated tablet contains 48 mg of lactose.
Der er kun begrænset erfaring med behandling af patienter med let til moderat nedsat nyrefunktion (se pkt.
Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4).
Methotrexatdoser over 20 mg ugentligt bør anvendes med forsigtighed sammen med Clopidogrel/Acetylsalicylic acid Mylan, da ASA kan hæmme den renale clearance af methotrexat, hvilket kan føre til knoglemarvstoksicitet.
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with Clopidogrel/Acetylsalicylic acid Mylan as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
Den almindeligste bivirkning, der er set med Clopidogrel/Acetylsalicylic acid Mylan, er blødning.
The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Mylan is bleeding.
Non-steroide antiinflammatoriske stoffer (NSAID'er) I et klinisk studie foretaget med raske forsøgspersoner øgede samtidig administration af clopidogrel og naproxen okkult gastrointestinalt blodtab.
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Respiratoriske lidelser, lidelser i thorax og mediastinum
Respiratory, thoracic and mediastinal disorders
• hvis du lider af en alvorlig nyresygdom.
• if you suffer from severe kidney disease.
Blå mærker Udslæt, kløe, hudblødning (purpura)
Rash, pruritus, skin bleeding (purpura)
I CAPRIE var den generelle forekomst af blødning 9,3 % hos patienter behandlet med enten clopidogrel eller ASA.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du tager Clopidogrel/Acetylsalicylic acid Mylan.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel/Acetylsalicylic acid Mylan.
Antallet af patienter, som oplevede det primære sammensatte endepunkt [kardiovaskulær død, myokardieinfarkt, apopleksi eller refraktær iskæmi] var 1.035 (16,5 %) i clopidogrel plus ASAgruppen og 1.187 (18,8 %) i ASA-gruppen, hvilket giver en relativ risikoreduktion på 14 % (95 % CI: 6 %-21 %; p = 0,00005) for clopidogrel plus ASA-gruppen.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group.
Mavesår og duodenalt ulcus, gastritis, opkastning, kvalme, obstipation, flatulens
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
Sikkerheden ved samtidig administration af clopidogrel/acetylsalicylsyre og andre trombolytika er ikke fastlagt, og der skal derfor udvises forsigtighed (se pkt.
The safety of the concomitant administration of clopidogrel/acetylsalicylic acid with other thrombolytic agents has not been formally established and should be undertaken with caution (see section 4.4).
Samtidig administration af Clopidogrel/Acetylsalicylic acid Mylan og orale antikoagulantia kan ikke anbefales, da det kan øge blødningsintensiteten (se pkt.
The concomitant administration of Clopidogrel/Acetylsalicylic acid Mylan with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.4).
• hvis du lider af en nyre- eller leversygdom.
• if you have kidney or liver disease.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket.
If you get any side effects, talk to your doctor, or pharmacist.
Tabletkernen:
Tablet core
Erfaring med behandling af patienter med moderat alvorlige leversygdomme, hvor der kan være disposition for blødning, er begrænset (se pkt.
Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4).
Lidelser i det centrale og perifere nervesystem
Nervous system disorders
Gastrointestin al blødning, diaré, mavesmerter, dyspepsi
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
Øvrige indholdsstoffer: - Tabletkernen: Mikrokrystallinsk cellulose, lactose (se afsnit 2 'Clopidogrel/Acetylsalicylic acid Mylan indeholder lactose'), croscarmellosenatrium, hydroxypropylcellulose, kolloid vandfri silica, talkum, hydrogeneret ricinusolie, pregelatineret stivelse, stearinsyre, gul jernoxid (E172).
Tablet core: microcrystalline cellulose, lactose (see section 2 ‘Clopidogrel/Acetylsalicylic acid Mylan contains lactose'), croscarmellose sodium, hydroxypropylcellulose, colloidal anhydrous silica, talc, hydrogenated castor oil, pregelatinized starch, stearic acid, iron oxide yellow (E172).
- Filmovertræk: Hypromellose, triacetin, talkum, polyvinylalkohol (delvist hydrolyseret), titandioxid (E171), glycerol monocaprylocaprat (E422), natriumlaurilsulfat, gul jernoxid (E172)
Tablet coating: hypromellose, triacetin, talc, poly (vinyl alcohol) (partially hydrolysed), titanium dioxide (E171), glycerol monocaprylocaprate (E422), sodium lauril sulfate, iron oxide yellow (E172)
Clopidogrel/Acetylsalicylic acid Mylan indeholder lactose.
Clopidogrel/Acetylsalicylic acid Mylan contains lactose.
Som forholdsregel bør amning ophøre under behandling med Clopidogrel/Acetylsalicylic acid Mylan.
Breast-feeding should be discontinued during treatment with Clopidogrel/Acetylsalicylic acid Mylan.
Virkning og anvendelse af Clopidogrel/Acetylsalicylic acid Mylan Det skal du vide, før du begynder at tage Clopidogrel/Acetylsalicylic acid Mylan Sådan skal du tage Clopidogrel/Acetylsalicylic acid Mylan Bivirkninger
What Clopidogrel/Acetylsalicylic acid Mylan is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan How to take Clopidogrel/Acetylsalicylic acid Mylan Possible side effects
Farmakoterapeutisk klassifikation: klassifikation: ATC-kode: Antitrombotiske midler blodpladeaggregationshæmmere ekskl.
Pharmacotherapeutic group: group: ATC code: Antithrombotic agents, platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30.
Patienterne blev randomiseret til clopidogrel (300 mg initial støddosis efterfulgt af 75 mg/dag, N = 6.259) plus ASA (75-325 mg en gang daglig) eller ASA alene (N = 6.303), (75325 mg en gang daglig) i kombination anden standardbehandling.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
Patienter skal vejledes vedrørende risikoen for skader og blødning i mave-tarm-kanalen, hvis de drikker alkohol under behandlingen med clopidogrel plus ASA, især hvis alkoholforbruget er kronisk eller stort (se pkt.
Patients should be counselled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy (see section 4.4).
Patienterne fik clopidogrel (300 mg støddosis efterfulgt af 75 mg daglig, n = 1.752) plus ASA eller ASA alene (n = 1.739) (150-325 mg som støddosis, herefter 75-162 mg daglig), et fibrinolytisk middel samt - når det var hensigtsmæssigt - heparin.
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Hospitalsindlæggelse er nødvendig ved indtagelse af toksisk dosis.
If a toxic dose has been ingested then admission to hospital is necessary.
Til oral anvendelse.
Method of administration For oral use.
Feber, ødem
Fever, oedema*
Blisterkort af aluminium med et lag af tørremiddel i kartonæsker, der indeholder 28 eller 30 filmovertrukne tabletter.
Aluminium blisters with desiccant layer containing 28 or 30 film-coated tablets.
Er du i tvivl, så spørg lægen eller apotekspersonalet.
If you have any further questions, ask your doctor, or pharmacist.
- Filmovertræk: Hypromellose, triacetin, talkum, polyvinylalkohol (delvist hydrolyseret), titandioxid (E171), glycerol monocaprylocaprat (E422), natriumlaurilsulfat, Allura Red AC (E129) (se afsnit 2 'Clopidogrel/Acetylsalicylic acid Mylan indeholder Allura Red AC) Udseende og pakningsstørrelser for Clopidogrel/Acetylsalicylic acid Mylan
Tablet coating: hypromellose, triacetin, talc, poly (vinyl alcohol) (partially hydrolysed), titanium dioxide (E171), glycerol monocaprylocaprate (E422), sodium lauril sulfate, Allura Red AC (E129) (see section 2 ‘Clopidogrel/Acetylsalicylic acid Mylan contains Allura Red AC')
Akut leversvigt, leverskader, primært hepatocellulær hepatitis, forhøjede leverenzymer
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic enzymes*, abnormal liver function test, chronic hepatitis*
I litteraturen er der kun få tilgængelige data, der tillader en vurdering af det kliniske udbytte af CYP2C19-genotypebestemmelse i asiatiske befolkningsgrupper.
From literature, limited data in Asian populations are available to assess the clinical implication of genotyping of this CYP on clinical outcome events.
I overensstemmelse med resultaterne ovenfor, blev det vist i en metaanalyse af 6 studier med 335 clopidogrelbehandlede ved steady state, at eksponeringen for den aktive metabolit nedsattes med 28 % for personer med moderat metabolisme, og 72 % for personer med ringe metabolisme.
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Clopidogrel/Acetylsalicylic acid Mylan skal anvendes med forsigtighed til patienter i samtidig behandling med glykoprotein IIb/IIIa-hæmmere (se pkt.
Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
- heparin eller anden medicin til indsprøjtning til at nedsætte dannelse af blodpropper, - ticlopidin, eller anden medicin mod blodpropper, - selektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression,
oral anticoagulants, medicines used to reduce blood clotting, ASA or another non-steroidal anti-inflammatory medicine usually used to treat painful and/or inflammatory conditions of muscle or joints, heparin or any other injectable medicine used to reduce blood clotting, ticlopidine, other antiplatelet agents, a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Du skal holde op med at tage andre lægemidler, der indeholder clopidogrel, mens du tager Clopidogrel/Acetylsalicylic acid Mylan.
You should stop other clopidogrel treatment while you are taking Clopidogrel/Acetylsalicylic acid Mylan.
Perforerede, enhedsdosis-blisterkort af aluminium med et lag af tørremiddel i kartonæsker, der indeholder 28 eller 30 filmovertrukne tabletter.
Aluminium perforated unit dose blisters with desiccant layer containing 28 or 30 film-coated tablets.
Antallet af patienter, som oplevede det primære endepunkt [kardiovaskulær død (CV), myokardieinfarkt (MI) eller apopleksi] var 582 (9,3 %) i clopidogrel plus ASA-gruppen og 719 (11,4 %) i ASA-gruppen, hvilket giver en relativ risikoreduktion på 20 % (95 % CI: 10 %-28 %; p = 0,00009) for clopidogrel plus ASA-gruppen (en relativ risikoreduktion (RR) på 17 %, når patienterne fik konservativ behandling, 29 %, når de fik ballonudvidelse (perkutan transluminal koronar angioplastik (PTCA)) med eller uden stent, og 10 %, når de fik koronar bypassoperation (CABG).
ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Da Clopidogrel/Acetylsalicylic acid Mylan indeholder ASA, er det kontraindiceret i graviditetens tredje trimester.
Due to the presence of ASA, Clopidogrel/Acetylsalicylic acid Mylan is contraindicated during the third trimester of pregnancy.
Det er usandsynligt, at Clopidogrel/Acetylsalicylic acid Mylan vil påvirke din evne til at køre bil eller betjene maskiner.
Driving and using machines Clopidogrel/Acetylsalicylic acid Mylan should not affect your ability to drive or to use machines.
Efter gentagen dosering med clopidogrel 75 mg daglig var hæmningen af ADP-induceret trombocytaggregation lavere (25 %) hos forsøgspersoner med alvorlig nyresygdom (kreatininclearance 5-15 ml/min) end den, der blev set hos raske forsøgspersoner.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Der foreligger ingen data fra anvendelse af clopidogrel/acetylsalicylsyre til gravide kvinder.
No clinical data on exposure to clopidogrel/acetylsalicylic acid during pregnancy are available.
Det vides ikke, om ASA-dosen i Clopidogrel/Acetylsalicylic acid Mylan påvirker fertiliteten.
It is unknown whether ASA dose in Clopidogrel/Acetylsalicylic acid Mylan alters fertility.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg filmovertrukne tabletter indeholder Allura Red AC, hvilket kan forårsage allergiske reaktioner.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets contain Allura Red AC which may cause allergic reactions.
Samtidig administration af metamizol kan reducere den trombocytaggregerende effekt af ASA.
Metamizole may reduce the effect of ASA on platelet aggregation when taken concomitantly.
Generelle symptomer og forstyrrelser ved applikationssted
General disorders and administration site conditions